DeCure for Cerebral amyloid angiopathy, APP-related
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for cerebral amyloid angiopathy, APP-related — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCerebral amyloid angiopathy, APP-related maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cerebral amyloid angiopathy, app-related is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SPG11 vesicle trafficking associated, spatacsin (SPG11) — SPG11 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8YAH · 3.3 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2021 review notes that amyloid-β immunotherapy, such as the then-recently approved aducanumab for Alzheimer disease, is associated in clinical trials with a high rate of amyloid-related imaging abnormalities. The review proposes that coexisting cerebral amyloid angiopathy may drive these abnormalities and could modify the efficacy of immunotherapy in patients. It discusses strategies to identify cerebral amyloid angiopathy in patients being considered for such treatment but provides no trial data on any drug for cerebral amyloid angiopathy itself.
A 2016 review describes amyloid precursor protein as evolutionarily conserved and expressed in endothelial cells of cerebral and peripheral arteries. It discusses mechanisms of APP expression and proteolytic cleavage in endothelial cells and their physiological and pathological implications, but reports no therapeutic intervention or outcome data.
A 2009 review states that cerebral amyloid angiopathy is closely associated with intracerebral hemorrhage and notes progress in understanding its etiology, pathogenesis, diagnosis, and treatment. It does not name any specific drug or report any survival or response rates.
No abstract reports a drug tested specifically for cerebral amyloid angiopathy related to APP. No concrete numbers on survival, response rates, or sample sizes are given. What is missing is any clinical trial of a drug for this condition, any patient stratification by APP mutation status, and any funding for such a trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Stroke · 2021 · 58 citations · open access
Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab
AbstractWe review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-β immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy's efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.
Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium
AbstractAmyloid precursor protein (APP) is evolutionary conserved protein expressed in endothelial cells of cerebral and peripheral arteries. In this review, we discuss mechanisms responsible for expression and proteolytic cleavage of APP in endothelial cells. We focus on physiological and pathological implications of APP expression in vascular endothelium.
AbstractCerebral amyloid angiopathy is closely associated with intracerebral hemorrhage. In recent years, a further understanding of etiology, pathogenesis, diagnosis and treatment on cerebral amyloid angiopathy-related intracerebral hemorrhage has been achieved.
Key words:
cerebral amyloid angiopathy; cerebral hemorrhage; apolipoproteins E; amyloid β-protein
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
